CSI Market
Sign In | Register

Cue Biopharma Inc (CUE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CUE quarterly Cash Flow →
The quarterly cash flow data below helps track how Cue Biopharma Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-26.60
Depreciation & amortization0.96
Amortization of Other Assets-0.18
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.03
Share-based Compensation4.74
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Deferred Rent-
Increase Decrease In Research And Development Contract Advances-
Increase Decrease In Accrued Compensation And Related Expense-
Increase Decrease In Research And Development Contract Liabilities-
Common Stock To Be Issued Pursuant To License Agreements-
Operating Lease Rent Payments-
Operating Lease Right Of Use Amortization-
Other Non Cash Charges-
Increase Decrease In Operating Lease Liabilities-2.57
Increase Decrease In Operating Lease Right Of Use Assets-
Change In Operating Lease Right Of Use Asset2.52
Accretion Of Final Payment On Term Loan0.13
Increase Decrease In Deposit Liabilities1.13
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-4.60
Increase (Decrease) in Accounts Payable1.13
Increase (Decrease) in Accrued Liabilities-1.30
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.12
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities4.04
Discontinued operations0.00
Net Cash flow from Operating Activities-21.69
Investing Activities
Capital Expenditures-0.18
Sale of Capital Items0.04
Payments to Acquire Short-term Investments0.00
Payments to Acquire Marketable Securities-16.29
Real Estate Investments0.00
Payments For Redemption Of Short Term Investments16.50
Maturity And Payments For Redemption Of Short Term Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.08
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock28.29
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits0.00
Other financing activities net0.00
Other net0.00
Payments Of Deferred Public Offering Costs-
Proceeds From Sale Of Placement Agent And Underwriters Warrants-
Proceeds From Exercise Of Common Stock-
Proceeds From At Time Market Offering Net Of Commission And Fees2.50
Payment Of Term Loan-4.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities26.29
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-21.82
Total Cash Flow4.68
4 historic quarters locked

Sign in to unlock the full Cue Biopharma Inc cash flow history.

Sign In Create Free Account

About Cue Biopharma Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 16, 2026
  • Source: cue-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-108287

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License